Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease

All patients will receive an haploidentical hematopoietic stem cell transplant with the following conditioning and GvHD prevention: Pre-transplant immunosuppressive therapy: 2 cycles of Fludarabine and Dexamethasone x 5 days each cycle Conditioning regimen: rATG daily x 3 days, Fludarabine daily x 6 days and Busulfan daily x 4 days GVHD prophylaxis: Cyclophosphamide day +3 and +4, Tacrolimus and Mycophenolate mofetil

A Pilot Study of Pre-transplant Immunosuppressive Therapy for Haploidentical Transplants in Patients With Sickle Cell Disease

This is a study to evaluate the safety and toxicity of a treatment regimen consisting of 2 cycles of pre-transplant immunosuppressive therapy followed by myeloablative preparative regimen and allogeneic hematopoietic stem cell transplantation from a haploidentical donor in patients with sickle cell disease. The overall goal of this study is to expand the donor pool for hematopoietic stem cell transplantation in sickle cell disease using haploidentical donors, and to develop a non-toxic, myeloablative regimen, with the goal of achieving a consistent donor chimerism utilizing pre-transplant immunosuppressive therapy.

Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease

Recruitment

Summary

Participation Requirements

Description

Tracking Information